United States

Background. Psychiatric comorbidities are known to worsen cardiovascular (CV) outcomes, but their specific impact on all-cause hospital readmissions in heart failure (HF) populations remains unclear. While prior studies emphasize all-cause 30-day readmission, limited research explores how individual psychiatric conditions influence readmission risk over both short- and long-term periods. All-cause readmissions significantly contribute to healthcare utilization and financial burden, particularly among patients with complex psychosocial profiles. Identifying which psychiatric diagnoses are most strongly associated with all-cause readmission risk may inform the development of more precise and equitable post-discharge care strategies. 

Methods. We conducted a retrospective cohort analysis using the Nationwide Readmissions Database from 2016 to 2022. A total of 31,886,859 weighted hospitalizations were included. Adult patients (≥18 years) hospitalized for HF were stratified by psychiatric comorbidity, including depression, anxiety, bipolar disorder, PTSD, schizophrenia/psychotic disorders, and substance use disorder. The primary outcomes were all-cause 30-day and 1-year readmissions. Multivariable Cox regression models adjusted for age, sex, hospital characteristics, income quartile, Charlson Comorbidity Index, and discharge disposition. 

Results. Schizophrenia/psychotic disorders were associated with the highest adjusted risk of all-cause readmission at both 30 days (HR 1.05, 95% CI 1.05–1.06, p&lt;0.001) and 1 year (HR 1.09, 95% CI 1.08–1.10, p&lt;0.001). Bipolar disorder (HR 1.03 [30-day], 1.06 [1-year]), PTSD (HR 1.03 [30-day], 1.05 [1-year]), and substance use disorder (HR 1.02 [30-day], 1.04 [1-year]) were also significantly associated with increased readmission risk (p &lt; 0.001 for all). Depression was associated with a small but statistically significant reduction in 30-day readmission (HR 0.99, p &lt; 0.001) but was not associated with 1-year readmission (HR 0.99, p = 0.69). Anxiety (HR 0.99 [30-day], 1.00 [1-year]) was not significantly associated with readmission at either time point (p = 0.86 and p = 0.99, respectively).

Conclusion. Psychiatric comorbidities, particularly schizophrenia, bipolar disorder, PTSD, and substance use disorder, are independent risk factors for short- and long-term all-cause readmissions after HF hospitalization. These findings underscore the importance of integrating psychiatric care into cardiovascular discharge planning and transitional care models. Targeted interventions that address mental health instability in the early recovery period may reduce preventable readmissions and improve long-term cardiovascular outcomes in this high-risk population.




AMA Research Challenge 2025 

Psychiatric Comorbidities Predict All-Cause Readmissions in Heart Failure

Congratulations to all the researchers who have qualified for the AMA Research Challenge virtual poster symposium and semifinals!

Welcome to the **largest national, multi-specialty research event** featuring research from nearly 1,000 medical students, residents, fellows, and international medical graduates across six topic areas - basic science, clinical and translational research, clinical vignettes, health systems science, medical education, and public health and health policy.

#### Access the Event
Use the buttons below or navigation menu to access the event. 

[![](https://assets.underline.io/markdown_image/1/image/d4076f2146939317a29eb9f69c53ad41.png)](https://underline.io/events/506/sessions?searchGroup=all)
[![](https://assets.underline.io/markdown_image/1/image/6bcee0b523a4874c4292ca0415d88dde.png)](https://underline.io/events/506/posters?searchGroup=all)

#### Event Details
The 2025 AMA Research Challenge includes the following symposium halls:
* **Semifinals hall:** Features research from 54 medical students, residents and international medical graduates that received top scores during first round scoring. 
* **Poster symposium hall:** Features research from nearly 1,000 medical students, residents and international medical graduates categorized by topics and subtopics.

**Here’s how to participate:**
* **View posters and presentations** on a variety of topics and specialties
* **Score posters in the semifinals** to help decide the top five finalists (AMA member exclusive opportunity)
* **Connect with presenters** and provide feedback to help advance their research
* **New this year: Watch live poster presentations** by topic area and engage directly with researchers

At the conclusion of this event, the AMA announced the top five finalists who advanced to the AMA Research Challenge final round, presented their research to an elite panel of judges, and competed to win a $10,000 grand prize presented by Laurel Road.

**Addison Shenk, a fourth-year medical student from Edward Via Virginia College of Osteopathic Medicine, was the winner of the 2025 AMA Research Challenge and was awarded the grand prize of $10,000, presented by Laurel Road.**

#### A message from Dr. Bobby Mukkamala, AMA President
<div style="position: relative; width: 100%; padding-bottom: 56.25%; height: 0; overflow: hidden;">
  <iframe 
    src="https://underline.io/embed/136894-ama-video?t=0"
    title="AMA Welcome Video"
    allowfullscreen
    style="position: absolute; top: 0; left: 0; width: 100%; height: 100%; border: 0;">
  </iframe>
</div>


#### Recognized Institutions
In 2025, 1,400 abstracts were submitted across six topic areas representing 174 medical schools and more than 150 residency and health care institutions. [See if your institution is represented this year!](https://drive.google.com/file/d/1eFrTqCmCeobx9pr5drJK2hllvsIpFNOY/view?usp=drive_link)

#### Grand Prize Sponsor
AMA would like to thank Laurel Road, a brand of KeyBank, for sponsoring a $10,000 grand prize for the winner of the AMA Research Challenge. Laurel Road and KeyBank are not involved in winner selection process. The winner will be announced during the AMA Research Challenge final round. Payment of the grand prize will be directly from Laurel Road/KeyBank. See the [AMA Research Challenge Official Rules for terms and conditions](https://www.ama-assn.org/system/files/research-challenge-official-rules.pdf).

[![](https://assets.underline.io/uploads/markdown_image/1/image/611e331d4a0eba0920f240cfc04b4d77.png)](https://www.laurelroad.com/)

#### Code of Conduct
<html>
AMA has a code of conduct for its meetings – we ask all attendees to adhere to this code to participate in this year’s meeting. Please read and <a href="https://www.ama-assn.org/about/code-conduct" target="_blank">learn more here</a> about your conduct requirements.
<br><br>
	</html>
	

#### Semifinals Judges

You need to log in with the email address you registered with. Access credentials have been sent to your email. 

Please be sure to check your spam and other email folders if you do not see an email confirmation right away.

Need help? Contact us at <support@underline.io>.

Please log in to explore this event.

If you have used the AMA Research Challenge platform previously, please click the ‘Log-in’ button below. If you do not remember your password, please click “forgot password” and follow prompts to reset your password. After resetting your password, please refresh your webpage to access the platform. 

Register to explore research in a variety of topics. AMA members get exclusive access to score posters in the semifinals. 

**Please use [this link here](https://www.ama-assn.org/member-benefits/events/ama-research-challenge) to register for free. **

Registration Is Required

Join the AMA Research Challenge poster symposium and semifinals to explore top research posters and score posters in the semifinals (an AMA member exclusive opportunity).

Background. Psychiatric comorbidities are known to worsen cardiovascular (CV) outcomes, but their specific impact on all-cause hospital readmissions in heart failure (HF) populations remains unclear. While prior studies emphasize all-cause 30-day readmission, limited research explores how individual psychiatric conditions influence readmission risk over both short- and long-term periods. All-cause readmissions significantly contribute to healthcare utilization and financial burden, particularly among patients with complex psychosocial profiles. Identifying which psychiatric diagnoses are most strongly associated with all-cause readmission risk may inform the development of more precise and equitable post-discharge care strategies. 

Methods. We conducted a retrospective cohort analysis using the Nationwide Readmissions Database from 2016 to 2022. A total of 31,886,859 weighted hospitalizations were included. Adult patients (≥18 years) hospitalized for HF were stratified by psychiatric comorbidity, including depression, anxiety, bipolar disorder, PTSD, schizophrenia/psychotic disorders, and substance use disorder. The primary outcomes were all-cause 30-day and 1-year readmissions. Multivariable Cox regression models adjusted for age, sex, hospital characteristics, income quartile, Charlson Comorbidity Index, and discharge disposition. 

Results. Schizophrenia/psychotic disorders were associated with the highest adjusted risk of all-cause readmission at both 30 days (HR 1.05, 95% CI 1.05–1.06, p<0.001) and 1 year (HR 1.09, 95% CI 1.08–1.10, p<0.001). Bipolar disorder (HR 1.03 [30-day], 1.06 [1-year]), PTSD (HR 1.03 [30-day], 1.05 [1-year]), and substance use disorder (HR 1.02 [30-day], 1.04 [1-year]) were also significantly associated with increased readmission risk (p < 0.001 for all). Depression was associated with a small but statistically significant reduction in 30-day readmission (HR 0.99, p < 0.001) but was not associated with 1-year readmission (HR 0.99, p = 0.69). Anxiety (HR 0.99 [30-day], 1.00 [1-year]) was not significantly associated with readmission at either time point (p = 0.86 and p = 0.99, respectively).

Conclusion. Psychiatric comorbidities, particularly schizophrenia, bipolar disorder, PTSD, and substance use disorder, are independent risk factors for short- and long-term all-cause readmissions after HF hospitalization. These findings underscore the importance of integrating psychiatric care into cardiovascular discharge planning and transitional care models. Targeted interventions that address mental health instability in the early recovery period may reduce preventable readmissions and improve long-term cardiovascular outcomes in this high-risk population.




poster

Background:Hydrochlorothiazide (HCTZ) is a commonly used thiazide diuretic prescribed to treat hypertension and fluid retention. While effective and generally well-tolerated, long-term use has been associated with an increased risk of cutaneous squamous cell carcinoma (SCC), potentially due to its photosensitizing effects. SCC, a prevalent non-melanoma skin cancer, is influenced by UV exposure and is more likely to develop in immunocompromised individuals, such as kidney transplant recipients—many of whom are prescribed HCTZ.
Objective:To investigate the association between HCTZ use and the incidence of SCC in kidney transplant recipients, with a focus on demographic variables.
Methods:A retrospective cohort analysis was performed using the TriNetX research platform. Kidney transplant patients were divided into two matched cohorts based on HCTZ exposure. SCC incidence was compared between the groups.
Results:Incidence and prevalence of SCC remained low in patients under 65 but increased sharply with age, peaking in the 75–79 group before declining in older cohorts. Native Hawaiian or Other Pacific Islander individuals had the highest incidence proportion, while Black and American Indian or Alaska Native groups had the lowest. Minimal sex-based differences were observed, and incidence was slightly higher among non-Hispanic patients compared to Hispanic individuals.
Discussion:This study underscores the increased risk of SCC in immunocompromised populations prescribed HCTZ. Notably, demographic factors such as race, sex, and age remain underrepresented in existing literature, yet are crucial for understanding individual risk profiles. 
Conclusion:HCTZ use in kidney transplant recipients may elevate SCC risk. Personalized risk assessment should be considered when prescribing HCTZ in this vulnerable population.

Hydrochlorothiazide as a Potential Risk Factor for Skin Cancer in Kidney Transplant Patients: A Retrospective Review

Background
Chronic pulmonary disease (CPD) has been previously correlated with delayed swallowing reflexes and discoordination between respiration and swallowing. This study aims to determine the influence of preoperative CPD on postoperative dysphagia rates in patients undergoing cervical spine surgery.

Methods
A prospectively collected multi-institutional quality registry was retrospectively reviewed. Both preoperative and postoperative (1, 3, and 12 months) Eating Assessment Tool-10 (EAT-10) dysphagia scores were collected to assess dysphagia in patients. A score ≥ 3 indicated dysphagia. Patients were grouped by whether they reported CPD preoperatively, which was self-identified during enrollment. Mixed-effects logistic regression models were generated to control for the confounding effects of additional factors and determine whether CPD independently correlated with postoperative dysphagia.

Results
Of 2,001 patients, 218 (10.9%) had preoperative CPD. Patients with CPD were significantly more likely to report dysphagia at baseline (25% vs. 14%, p< 0.001), 3 months (39% vs. 28%, p=0.003), and 12 months (43% vs. 24%, p< 0.001) but not at 1 month (65% vs. 55%, p=0.059). Within the subset of patients without baseline dysphagia (n=1,701), CPD patients (n=163) had significantly higher prevalence of developing dysphagia at 3 months (31% vs. 23% p = 0.040) and 12 months (29% vs. 19%) postoperatively but not at 1 month (54% vs. 52% p = 0.7). These patients also experienced a significantly worse trajectory in dysphagia severity between baseline and 12 months (2.587±4.364 vs. 1.759±4.322, p=0.006) despite similar baseline EAT-10 scores (0.110±0.401 vs. 0.118±0.413, p=0.8). Controlling for baseline dysphagia as a fixed effect, multivariable analyses demonstrated preoperative CPD independently predicted dysphagia at 12 months postoperatively (OR: 1.70, 95% Cl: 1.09–2.66, p=0.020) but not at 1 month (OR=0.92, 95% CI: 0.58–1.47, p=0.7) or 3 months (OR=1.26, 95% CI: 0.86–1.86, p=0.2).

Conclusion

CPD independently predicted dysphagia at 12 months after controlling for confounding, and this susceptibility was further reflected by the worse 12-month severity trajectory observed in CPD patients. Future research into the relationship between CPD and esophageal function throughout postoperative recovery would be valuable to better guide patient decision-making to undergo elective cervical spine surgery.



Chronic Pulmonary Disease Predicts Persistent Dysphagia Following Cervical Spine Surgery

Title
Comparative Effects of Statins and Fibrates on the Onset of Diabetic Retinopathy in Type 2 Diabetes

Background
Diabetic retinopathy (DR) is a common complication of type 2 diabetes mellitus (T2DM) and a leading cause of vision loss in working-age adults. Management often requires invasive, costly procedures to preserve vision and while lipid-lowering drugs (LLDs), particularly statins and fibrates, have shown promise in slowing DR progression, their role in disease onset remains unclear. This study evaluated the association between statin or fibrate therapy and DR onset to assess their prophylactic potential. 

Methods
This retrospective cohort study used de-identified electronic health records from 152 healthcare organizations via the TriNetX Global Network. Patients with T2DM and no prior ocular complications, diagnosed at least 10 years prior, were assigned to fibrate-only (n = 7,004) or statin-only (n = 463,588) cohorts. Drug exposure required two records: one within 6 months and one at least 1 year after diagnosis. After propensity score matching on demographic characteristics, retinal vascular and non-diabetic retinopathy conditions, and serum HDL, LDL, triglycerides, and HbA1c, each cohort included 6,691 patients. Outcomes included diagnosis of nonproliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), or need for antiVEGF injections or retinal laser. Patients with outcomes prior to cohort entry were excluded.

Results
Fibrate therapy was associated with lower risk of DR across all stages: 55.1% reduction in mild NPDR (RR = 0.449; 95% CI: 0.359, 0.561; p < 0.001), 68.7% in moderate (RR = 0.313; 95% CI: 0.202, 0.486; p < 0.001), 65.3% in severe (RR = 0.357; 95% CI: 0.174, 0.735; p < 0.004), and 67.6% in PDR (RR = 0.324; 95% CI: 0.203, 0.517; p < 0.001). Onset was also delayed: mild (log-rank x2 = 25.238; p < 0.001), moderate (log-rank x2 = 17.419; p < 0.001), severe (log-rank x2 = 5.140; p < 0.024), and PDR (log-rank x2 = 15.125; p < 0.001).
Fibrate users had a 66.7% reduced risk of retinal laser (RR = 0.333; 95% CI: 0.212, 0.524; p < 0.001) and longer time-to-event (log-rank x2 = 14.372; p < 0.001). No difference was found in antiVEGF injection risk. 

Conclusion
Fibrate therapy was associated with reduced risk and delayed onset of DR in patients with T2DM compared to statin therapy. These findings support a potential role for fibrates in DR prophylaxis.


The Comparative Effects of Statins and Fibrates on the Onset of Diabetic Retinopathy in Type 2 Diabetes

Abstract Title
Double Trouble: Lynch syndrome and KRAS Mutation in a Young Male With Stage IV Colon Adenocarcinoma

Background
Lynch syndrome is a hereditary cancer syndrome caused by germline mutations in mismatch repair (MMR) genes, resulting in microsatellite instability (MSI) and a significantly increased lifetime risk of early-onset colorectal cancer (50%–70%). KRAS mutations, frequently observed in sporadic colorectal cancers, are less commonly associated with Lynch syndrome. Their presence can influence both prognosis and response to targeted therapies, especially anti-epidermal growth factor receptor (EGFR) agents.

Case Presentation
A 35-year-old man with a history of lumbar radiculopathy and diverticulosis presented in August 2020 with diffuse abdominal pain and altered bowel habits. An abdominal CT scan revealed hepatic metastases, and colonoscopy identified a circumferential, partially obstructing mass in the distal descending colon. Biopsy confirmed a moderately differentiated adenocarcinoma, consistent with colorectal cancer (CRC) with distant metastasis (stage IV).
In October 2020, immunohistochemistry demonstrated loss of MLH1, MSH6, and PMS2 expression, consistent with deficient mismatch repair (dMMR) and suggestive of Lynch syndrome. Molecular profiling revealed a concurrent KRAS mutation. The patient was initiated on FOLFOX chemotherapy (5-fluorouracil, leucovorin, and oxaliplatin), administered biweekly, and completed five cycles by November 2020. His current status is unknown, as he was lost to follow-up.

Discussion
The co-occurrence of dMMR, consistent with Lynch syndrome, and a KRAS mutation presents diagnostic and therapeutic complexity in metastatic CRC. While dMMR or MSI-high (MSI-H) status predicts robust responses to immune checkpoint inhibitors, concurrent KRAS mutations can negate the benefit of anti-EGFR therapies and may influence overall prognosis.
In this case, early genomic profiling identified both Lynch syndrome and a somatic KRAS mutation. This guided the decision to initiate FOLFOX chemotherapy, in line with American Society of Clinical Oncology (ASCO) recommendations. However, recent evidence, including the KEYNOTE-177 trial (February 2016-2018) , supports the use of pembrolizumab as first-line therapy in MSI-H/dMMR metastatic CRC, demonstrating superior progression-free survival compared with standard chemotherapy (median, 16.5 vs 8.2 months).
Importantly, the presence of a KRAS mutation does not preclude benefit from immune checkpoint inhibitors. Studies demonstrate durable responses in dMMR/MSI-H tumors regardless of KRAS status. Given that KRAS mutations are found in 15% to 35% of Lynch-associated metastatic CRC cases, early and comprehensive molecular testing is essential to guide treatment, assess prognosis, and inform familial risk.
This case underscores the evolving role of precision oncology in tailoring individualized treatment by integrating germline and somatic genomic data.

Double Trouble: Lynch Syndrome and KRAS Mutation in a Young Male With Stage IV Colon Adenocarcinoma

Background
Second generation antipsychotics (SGAs) are widely used for managing psychiatric conditions due to their favorable side effect profile in comparison to first-generation agents, particularly their lower risk of extrapyramidal (EPS) symptoms. Despite their favorable profile, SGAs still carry a risk of EPS. This case highlights the course and treatment of EPS symptoms following administration of a long-acting SGA: Invega (paliperidone ER).

Case Presentation
This is a 30-year-old male with a past medical history of bipolar disorder type I who presented to our facility with diffuse muscle rigidity following recent injections of Invega. He experienced a manic episode requiring an inpatient psychiatric hospital stay 9 days prior to his presentation. During that admission he received 2 injections of Invega over the course of his 4 day stay. Post-discharge, he developed progressive muscle rigidity, facial expression changes, and weakness. These symptoms worsened over the next 5 days, at which point he presented. 

When he initially presented his major concerns were stiffness and slowness of movements. He was accompanied by his sister who corroborated his primary concerns and also noted diminished facial expressions. His examination displayed lead-pipe rigidity of the extremities with mild cog-wheeling, masked-facies, bradykinesia, and a shuffling gait. He was tachycardic and afebrile. Labs were significant for a mildly elevated CK at 235 IU/L, lactic acidosis, and serum lithium level within normal limits. He was admitted for further management and workup of EPS and was started on benztropine. NMS was considered as a diagnosis given recent antipsychotic exposure, rigidity, and tachycardia. However, the absence of fever and significant CK elevation ruled it out.

Following two days of benztropine therapy the patient’s rigidity, bradykinesia and facial animations improved and were markedly better by discharge. The patient reported feeling closer to his baseline. He was discharged with a 1 month supply of benztropine and instructions to follow up with psychiatry as an outpatient.


Discussion
This case underscores the need for vigilance when prescribing long-acting SGAs, as EPS can emerge and persist due to their prolonged pharmacokinetics. While SGAs are less likely to cause EPS, they still are capable of creating the discomforting constellation EPS symptoms. This patient’s clinical features aligned well with drug-induced parkinsonism, a subtype of EPS. The gradual onset of this patient’s symptoms and temporal relation to Invega administration were key in making this diagnosis. Clinicians should be aware of the prolonged action of Invega necessitating further follow-up as an outpatient.


A Case of Extrapyramidal Symptoms with a Long-Acting Second-Generation Antipsychotic

Background
Neurofibromatosis type 1 (NF1)—von Recklinghausen’s disease—results from mutations in the NF1 gene, leading to the absence of neurofibromin, a tumor suppressor protein. This loss promotes uncontrolled cell growth and tumor formation. NF1 presents variable clinical features, including: Cafe-au-lait macules, neurofibromas, freckling, Lisch nodules, scoliosis, pseudarthrosis, and neurological abnormalities including cognitive dysfunction and developmental delay. The genitourinary tract is rarely involved. When affected, symptoms may include recurrent urinary tract infections (UTIs), hematuria, and irritative urinary symptoms. Obstructive symptoms and urinary retention are less common and are typically associated with plexiform neurofibromas that affect multiple nerve fascicles. We present a case of an adult male with neurofibromatosis type 1 (NF1) who developed extensive systemic neurofibromas leading to recurrent urinary tract infections (UTIs) and septic shock. 

Case Presentation
We present a 31 year old male with a history of NF1, psychiatric disorders, functional quadriplegia, and numerous inoperable tumors. He developed sacral decubitus ulcers and extensive systemic neurofibromas leading to neurogenic bladder that required an indwelling Foley catheter for 1 to 2 years. This resulted in recurrent UTIs with multidrug-resistant bacteria, sepsis, and septic shock. A suprapubic catheter was placed to reduce the risk of recurrent UTIs. Despite this, he continued to experience recurrent UTIs and was readmitted with significant urine leakage around the suprapubic catheter site, severe sepsis, and acute kidney injury (AKI). Imaging revealed moderate to severe bilateral hydronephrosis and hydroureter, along with a new nodular focus along the posterior bladder wall, suspected to be a bladder neurofibroma. He also had multiple neurofibromas in the retroperitoneum, contributing to obstructive symptoms. Bilateral nephrostomy tubes were placed with frank pus noted in both tubes upon placement. Following this procedure, patient continued to experience episodes of fever, malaise, fatigue, and chills. The patient was admitted again with sepsis secondary to UTI, AKI and/or bacteremia. He responded well to a sepsis bundle and early antibiotic therapy and also underwent nephrostomy tube exchange. 

Discussion
The diagnosis of NF1 is primarily clinical. Genitourinary involvement in NF1 is uncommon. Symptoms may arise from mass effect, leading to recurrent UTIs, hematuria, dysuria, irritative symptoms, and, less commonly, obstructive symptoms. Malignant transformation of neurofibromas into malignant peripheral nerve sheath tumors can occur but is rare. Management of genitourinary involvement in NF1 is challenging and requires a multidisciplinary approach. Early diagnosis and intervention are crucial to prevent complications such as sepsis and kidney damage. 


Complications of Plexiform Neurofibromatosis of the Bladder leading to Neurogenic Bladder and Recurrent Sepsis

Abstract Title 
Primary Pancreatic Liposarcoma: A Rare Case and Presentation 

Background 
Primary pancreatic liposarcoma is an extremely rare malignancy, with fewer than ten documented cases between 1979 and 2016. Unlike more common epithelial pancreatic neoplasms, these tumors arise from mesenchymal tissue and often present diagnostic and management challenges. This is due to their rarity, variable imaging characteristics, and absence of standardized treatment protocols. This case offers insight into hospital-based diagnostic workup, imaging studies, and complex surgical management of a rare and aggressive tumor, highlighting several dilemmas frequently encountered in clinical practice. 

Case Presentation 
A 64-year-old woman with a history of breast cancer and a benign thyroid nodule presented with upper abdominal and back pain. Laboratory studies showed elevated alkaline phosphatase, with otherwise unremarkable tumor markers. CT imaging revealed a 10.0 cm heterogeneously enhancing pancreatic tail mass with coarse calcifications causing mass effect on the left kidney. Endoscopic ultrasound-guided fine-needle aspiration confirmed a hyperechoic mass with calcifications; pathology demonstrated malignant cells and osteoblast-like giant cells, consistent with dedifferentiated liposarcoma. 

The patient underwent extensive surgical resection, including distal pancreatectomy, nephrectomy, adrenalectomy, and resection of adjacent bowel segments. Follow-up imaging two months post-operatively revealed multiple hypoenhancing hepatic lesions and metastatic lymphadenopathy, confirmed on biopsy to be consistent with metastatic dedifferentiated liposarcoma. Despite initial surgical success, the disease rapidly recurred locally and metastatically. Radiotherapy and chemotherapy were deferred due to the patient’s clinical decline. She passed away shortly thereafter. 

Discussion 
This case illustrates multiple clinical dilemmas relevant to patient care. Radiologically, the absence of typical liposarcoma features, such as intralesional fat, and the presence of coarse calcifications underscore the diagnostic uncertainty associated with rare tumors such as pancreatic liposarcoma. Therapeutically, it highlights the challenges of managing aggressive malignancies for which no consensus guidelines exist. Despite complete resection, the patient experienced rapid recurrence, emphasizing the limited curative potential of surgery alone in dedifferentiated pancreatic tumor subtypes. From an educational perspective, this case reinforces the importance of maintaining a broad differential diagnosis for atypical pancreatic masses and highlights the need for interdisciplinary coordination in tumor board review, surgical planning, and palliative decision-making. This case underscores the value of recognizing rare tumor variants in hospital practice, managing rapid postoperative recurrence, and balancing aggressive intervention with patient-centered care in the absence of evidence-based treatment algorithms.

Primary Pancreatic Liposarcoma: A Rare Case and Presentation

Abstract Title
Interventions to Improve Post-Acute Care Linkage to Outpatient Treatment for Alcohol Use Disorder: A Systematic Review 

Ariyani Challapalli, BA1; Lisa Bero, PhD2; Kelsey Hills-Dunlap, MD3; Susan L. Calcaterra, MD, MPH, MS4,5; E. Jennifer Edelman, MD, MHS6,7; Gina R. Kruse, MD, MS, MPH5, Ben Harnke MLIS8; Eden Y. Bernstein, MD, MPH4

1 University of Colorado School of Medicine, Aurora, CO, USA
2 Center for Bioethics and Humanities, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
3 Division of Pulmonary Sciences & Critical Care, Department of Medicine, University of Colorado, Aurora, CO, USA
4 Division of Hospital Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA
5 Division of General Internal Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA
6 Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
7 Program in Addiction Medicine, Yale School of Medicine, New Haven, CT, USA.
8 Health Sciences Library, University of Colorado Anschutz Medical Campus, Aurora, CO, USA



Background
In the United States, alcohol use contributes to nearly 180,000 annual deaths, and over 2 million adults with alcohol use disorder (AUD) are hospitalized annually. While hospitalizations provide opportunities for AUD treatment engagement, fewer than half of patients with AUD attend outpatient follow-up after discharge. We are conducting a systematic review to synthesize evidence regarding interventions that facilitate linkage to outpatient AUD treatment following acute care admissions. 

Methods
We conducted a search for English language observational studies and randomized trials published from January 2000 to February 2025 that included MeSH and text (title/abstract) terms for AUD, outpatient treatment, and acute care admissions. Two reviewers evaluated studies for inclusion in a two-phase process (title/abstract followed by full text) based on pre-defined criteria related to outcomes, study design, population, setting, and publication eligibility. Ongoing studies from ClinicalTrials.gov from January 2019 to January 2025 were included. Other database sources were Ovid MEDLINE, Embase, PsycINFO, CINAHL, and Cochrane CENTRAL. Outcome criteria involved presence of a reported linkage to outpatient care defined as attendance to a setting where AUD treatment can be delivered, including primary care or specialty addiction treatment. Population included studies with adults age ≥18 years and >50% diagnosed with AUD or alcohol dependence. Setting included acute care admissions to hospitals and detoxification facilities but excluded residential treatment and emergency department visits. 

Results
The database search identified 4,827 unique citations, of which 4,720 were excluded during title and abstract review. Of the remaining 107 articles, 80 were excluded during full-text review: 33 (41%) were excluded due to lack of linkage to care outcome, 22 (28%) for study design, 15 (19%) for population, 8 (10%) for publication ineligibility, and 2 (3%) for setting. Of the 27 studies that met inclusion criteria, 16 (59%) were randomized controlled trials, 5 (19%) were non-randomized trials, 4 (15%) were ongoing studies, and 2 (7%) were observational studies. Of the interventions, 11 (41%) included brief interventions or motivational interviewing, 5 (19%) included medication initiation, 5 (19%) included peer or family member intervention, 4 (15%) included digital interventions, and 3 (7%) included referral strategies for outpatient treatment. Data extraction is ongoing. 


Conclusion
In this comprehensive systematic review, we identified 27 studies, including 16 randomized controlled trials, that describe interventions to link patients hospitalized with AUD to outpatient treatment. Ongoing data extraction will inform system-level design and implementation of interventions to improve outcomes in this population. 


Interventions to Improve Post-Acute Care Linkage to Outpatient Treatment for Alcohol Use Disorder: A Systematic Review

The Physician Payments Sunshine Act (2010) increased transparency in physician–industry financial relationships. This study examined industry payments to orthopaedic residency program directors (RPDs) and department chairs (RPCs) using Open Payments data from 2017–2023. Among 209 programs (209 PDs, 169 DCs), 95% received 41,465 payments totaling $126.3M. Most payments were under $1,000 and for Food & Beverage (PDs 60.7%, DCs 47.5%). Trauma RPDs and Arthroplasty RPCs had the highest average payments, while Trauma specialists received the greatest total. Funding was predominantly from Smith & Nephew (26%) and Stryker (21.6%), and disproportionately directed to males (91.1%) and MDs (88.9%). Industry funding to orthopaedic leaders is nearly universal, concentrated in certain subspecialties, and largely provided by a small number of companies.

Industry Payments to Orthopaedic Surgery RPDs and RPCs

Abstract Title
Non-Surgical Management of a Partial ACL Tear with Platelet-Rich Plasma: A Case Report

Background
Anterior cruciate ligament (ACL) injuries are common in pivoting sports and often result in long-term functional limitations. While complete ACL tears typically require surgical intervention, partial tears in active individuals may benefit from biologic therapies. We present a case of a recreational athlete with a partial ACL tear managed successfully with platelet-rich plasma (PRP) therapy.

Methods
A 29-year-old male recreational basketball player presented with acute right knee pain after landing awkwardly from a jump. He reported a mild "pop" sensation, immediate swelling, and difficulty bearing weight. He had no prior history of major knee injury. Initial conservative management included RICE and NSAIDs. Due to persistent pain and instability after 3 weeks, he was referred for further evaluation.

Results
Physical examination revealed mild effusion, tenderness along the medial joint line, and mild limitations in flexion and extension. Lachman test was mildly positive; anterior drawer test showed minimal translation. MRI demonstrated a partial tear of the ACL involving approximately 50% of the ligament fibers, with intact menisci and collateral ligaments. No chondral defects were noted. Given the partial nature of the injury and the patient's desire to avoid surgery, PRP therapy was recommended. The patient received two ultrasound-guided intra-ligamentous PRP injections over a four-week interval.

Conclusion
At the 3-month follow-up, the patient reported significant improvement in knee stability and function, with minimal pain. MRI demonstrated improved fiber continuity and decreased signal intensity in the ACL region. By 4 months post-injection, the patient had resumed non-contact basketball activity and continued with progressive strengthening and proprioception training. This case highlights the potential role of PRP therapy as a non-surgical treatment option in partial ACL tears, particularly in motivated patients seeking to return to activity. Further research is needed to better define indications and long-term outcomes of biologic therapies in ligamentous injuries.

Premium content

Next from AMA Research Challenge 2025

Hydrochlorothiazide as a Potential Risk Factor for Skin Cancer in Kidney Transplant Patients: A Retrospective Review

Similar lecture

Healthcare Utilization and Predictors of Readmission After Immunotherapy in a National Cohort